Peter Johansson
0000-0003-3781-4721
Publication & Citation Trends
Publications
0 total
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. OA
Cited by 19
Semantic Scholar
Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction. OA
Cited by 26
Semantic Scholar
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials OA
Cited by 0
Semantic Scholar
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial OA
Cited by 53
Semantic Scholar
Sickness Behavior in Community-Dwelling Elderly: Associations with Impaired Cardiac Function and Inflammation
Cited by 4
Semantic Scholar
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 OA
Cited by 86
Semantic Scholar
MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58 OA
Cited by 2
Semantic Scholar
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study
Cited by 29
Semantic Scholar
Research Topics
Myeloproliferative Neoplasms: Diagnosis and Treatment
(51)
Chronic Myeloid Leukemia Treatments
(17)
Hemoglobinopathies and Related Disorders
(16)
Acute Myeloid Leukemia Research
(15)
Eosinophilic Disorders and Syndromes
(15)
Affiliations
Linköping University
Center for Global Development
Sahlgrenska University Hospital
NU Hospital Group
Essen University Hospital